GT Biopharma (GTBP) Net Income towards Common Stockholders (2010 - 2026)

GT Biopharma (GTBP) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 334.15% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was -$37.0 million, a 217.36% decrease from a year earlier, with the FY2025 full-year figure at -$34.4 million, down 161.73% from the prior year.
• Net Income towards Common Stockholders was -$3.4 million for Q1 2026 at GT Biopharma, up from -$7.5 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $4.1 million in Q3 2025 and troughed at -$30.3 million in Q2 2025.
• A 5-year average of -$5.1 million and a median of -$3.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The widest YoY moves for Net Income towards Common Stockholders: up 220.11% in 2025, down 715.47% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$5.8 million in 2022, then soared by 48.98% to -$2.9 million in 2023, then declined by 28.05% to -$3.8 million in 2024, then plunged by 99.1% to -$7.5 million in 2025, then jumped by 55.18% to -$3.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$3.4 million (Q1 2026), -$7.5 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.